Beam Therapeutics Inc [NASDAQ: BEAM] loss -19.32% or -3.83 points to close at $15.99 with a heavy trading volume of 5147374 shares.
The daily chart for BEAM points out that the company has recorded -27.02% loss over the past six months.
If we look at the average trading volume of 2.28M shares, BEAM reached to a volume of 5147374 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Beam Therapeutics Inc [BEAM]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for BEAM shares is $44.31 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on BEAM stock is a recommendation set at 1.39. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
BofA Securities have made an estimate for Beam Therapeutics Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on March 28, 2025. The new note on the price target was released on March 10, 2025, representing the official price target for Beam Therapeutics Inc stock. On November 06, 2024, analysts increased their price target for BEAM shares from 27 to 39.
The Average True Range (ATR) for Beam Therapeutics Inc is set at 1.67, with the Price to Sales ratio for BEAM stock in the period of the last 12 months amounting to 25.31. The Price to Book ratio for the last quarter was 1.82, with the Price to Cash per share for the same quarter was set at 8.46.
Trading performance analysis for BEAM stock
Beam Therapeutics Inc [BEAM] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -18.87. With this latest performance, BEAM shares gained by 4.72% in over the last four-week period, additionally sinking by -27.02% over the last 6 months – not to mention a drop of -29.62% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BEAM stock in for the last two-week period is set at 35.88, with the RSI for the last a single of trading hit 30.37, and the three-weeks RSI is set at 38.26 for Beam Therapeutics Inc [BEAM]. The present Moving Average for the last 50 days of trading for this stock 21.35, while it was recorded at 19.16 for the last single week of trading, and 24.91 for the last 200 days.
Beam Therapeutics Inc [BEAM]: A deeper dive into fundamental analysis
Beam Therapeutics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 4.82 and a Current Ratio set at 4.82.
Beam Therapeutics Inc [BEAM]: An earnings per share (EPS) analysis
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for BEAM. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Beam Therapeutics Inc go to -1.00%.
An analysis of Institutional ownership at Beam Therapeutics Inc [BEAM]
The top three institutional holders of BEAM stocks are: FARALLON CAPITAL MANAGEMENT LLC with ownership of 7.91 million shares, which is approximately 9.6135%. VANGUARD GROUP INC, holding 7.9 million shares of the stock with an approximate value of $$185.11 million in BEAM stocks shares; and VANGUARD GROUP INC, currently with $$178.87 million in BEAM stock with ownership which is approximately 9.2749%.
